Somewhat Favorable Media Coverage Somewhat Unlikely to Affect Innoviva (INVA) Stock Price
News stories about Innoviva (NASDAQ:INVA) have been trending somewhat positive recently, Accern Sentiment Analysis reports. The research group identifies positive and negative media coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Innoviva earned a coverage optimism score of 0.20 on Accern’s scale. Accern also gave media stories about the biotechnology company an impact score of 45.3993304236583 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Here are some of the media stories that may have effected Accern Sentiment Analysis’s rankings:
- ETFs with exposure to Innoviva, Inc. : October 9, 2017 (finance.yahoo.com)
- Innoviva, Inc. (INVA) Earns Underweight Rating from Morgan Stanley (americanbankingnews.com)
- Critical Contrast: Innoviva (INVA) versus Sagent Pharmaceuticals (SGNT) (americanbankingnews.com)
- Innoviva, Inc. (INVA) Receives Average Rating of “Hold” from Analysts (americanbankingnews.com)
- Stocks With Rising Relative Price Strength: Innoviva (finance.yahoo.com)
A number of equities analysts have commented on INVA shares. Morgan Stanley restated an “underweight” rating and set a $8.00 price objective (up previously from $7.00) on shares of Innoviva in a research report on Friday, October 6th. Zacks Investment Research downgraded shares of Innoviva from a “hold” rating to a “sell” rating in a research report on Monday, July 3rd. Stifel Nicolaus restated a “neutral” rating on shares of Innoviva in a research report on Friday, September 15th. ValuEngine upgraded shares of Innoviva from a “hold” rating to a “buy” rating in a report on Monday, October 2nd. Finally, Cowen and Company set a $16.00 price target on shares of Innoviva and gave the company a “buy” rating in a report on Friday, July 28th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and two have issued a buy rating to the company. Innoviva currently has an average rating of “Hold” and an average price target of $13.60.
Innoviva (INVA) traded down 0.538% during trading on Wednesday, reaching $13.865. 293,112 shares of the company’s stock traded hands. Innoviva has a 12 month low of $8.67 and a 12 month high of $14.87. The company has a 50-day moving average of $13.80 and a 200 day moving average of $12.98. The stock has a market capitalization of $1.52 billion, a P/E ratio of 16.909 and a beta of 2.60.
Innoviva (NASDAQ:INVA) last issued its quarterly earnings results on Wednesday, July 26th. The biotechnology company reported $0.30 EPS for the quarter, topping the consensus estimate of $0.28 by $0.02. Innoviva had a net margin of 52.56% and a negative return on equity of 27.37%. The firm had revenue of $58.60 million for the quarter, compared to analysts’ expectations of $50.53 million. During the same period in the previous year, the business earned $0.13 earnings per share. Innoviva’s revenue for the quarter was up 80.3% compared to the same quarter last year. On average, equities research analysts expect that Innoviva will post $1.15 earnings per share for the current fiscal year.
Innoviva, Inc, formerly Theravance, Inc, is engaged in the development, commercialization and financial management of bio-pharmaceuticals. It focuses on the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate (FF)/vilanterol (VI)) and ANORO ELLIPTA (umeclidinium bromide/vilanterol (UMEC/VI)).
Receive News & Stock Ratings for Innoviva Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innoviva Inc. and related stocks with our FREE daily email newsletter.